




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 231/10, C07K 1/00, C07C 59/125, 51/367, 47/565, 69/708	A2	(11) International Publication Number: WO 98/17628 (43) International Publication Date: 30 April 1998 (30.04.98)
(21) International Application Number: PCT/GB97/02914 (22) International Filing Date: 22 October 1997 (22.10.97) (30) Priority Data: 9621985.2 22 October 1996 (22.10.96) GB (71) Applicant (for all designated States except US): PEPTIDE THERAPEUTICS LIMITED [GB/GB]; 321 Cambridge Science Park, Milton Road, Cambridge CB4 4WG (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): JOHNSON, Tony [GB/GB]; 10 Brookside Grove, Littleport, Ely, Cambs. CB6 1JN (GB). QUIBELL, Martin [GB/GB]; 23 Fennec Close, Cherry Hinton, Cambridge CB1 4GG (GB). (74) Agent: DAVIES, Jonathan, Mark; Reddie & Grose, 16 Theobalds Road, London WC1X 8PL (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>

(54) Title: A SOLID-PHASE TECHNOLOGY FOR THE PREPARATION OF AMIDES



(57) Abstract

A method for the solid phase synthesis of compounds of formula (1), in which either or both of R^1 or R^2 are combinatorially variable by a process represented by scheme (4) and wherein: X is (a), (b), (c) or (d); Y is H or a side chain functional group protective moiety such as Fmoc; R^2 is an intermediate form of R^2 which is subsequently chemically transformed to give the desired R^2 ; and n is between 2 and 12, preferably 4. The invention also provides compounds and combinatorial libraries of compounds of formula (1), as well as intermediate compounds for use in the method.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

- 1 -

A SOLID-PHASE TECHNOLOGY FOR THE PREPARATION OF AMIDES

5 Introduction


With the identification of a molecular target associated with a particular disorder, the medicinal chemist works towards a drug molecule which intervenes in a particular pathway preventing progression of the disorder. The route towards a potent and selective drug proceeds through a number of stages. For example, when faced with an aberrant protease, the protease is initially isolated and purified. An assay for activity is then established and a molecule that inhibits the proteolytic activity developed and systematically refined to provide a drug candidate with the desired potency and selectivity. This route is time consuming and expensive, thus tools which expedite a part of the whole process of drug development are extremely attractive commercially.

20 Combinatorial chemistry techniques, which are methods for the parallel preparation of many molecules compared to traditional single serial techniques, have the potential to play a pivotal role in the design and development of drug-like molecules. Co-pending UK Patent Application No. 25 9608457.9 describes a combinatorial library technology which has been developed as a tool to accelerate the development of inhibitors of proteolytic enzymes. A protease is screened against a large addressable library of potential protease substrates, swiftly providing an assay for proteolytic activity based upon internally quenched fluorescence. Along with the establishment of a

- 2 -

sensitive assay, a wealth of substrate structure-activity data is gathered which may be used in the design of an inhibitor. (Where legally permissible GB 9608457.5 is incorporated herein by reference).

5 A large proportion of the molecules that have previously or are currently being developed as protease inhibitors or in fact many other drug classes can be represented by the simple general formula (1).



Two fundamental approaches towards the preparation of molecules such as (1) are available. Traditionally, solution phase based serial chemistries have been used to provide single molecules. Recently these serial solution chemistries have begun to develop into parallel combinatorial methods in which R1 and/or R2 are varied providing 10's - 100's of molecules swiftly. Over the last 30 years, the expedient methods of solid phase chemistry have also developed. Solid phase methods have the potential to rapidly produce many thousands of molecules. However, the ease with which different classes of the general formula (1) can be varied in both R1 and R2 simultaneously depends upon the specific nature and functionality of R1 and R2. For example, when R1 and R2 are standard amino acid structures, providing the general class 'peptides', solid phase methods have developed sufficiently to provide single peptides or

10
15
20
25

- 3 -

thousands/millions of peptides in a combinatorial library format with relative ease.

Generally, protease inhibitors are designed with recognition elements from the substrate (i.e. R1), and are often coupled with a chemical moiety (i.e. R2) which interacts with the protease to inhibit proteolytic activity.

The combinatorial protease inhibitor library assay technique of GB 9608457.9 provides an example of parallel preparation of molecules (1) in which there is flexible combinatorial variation of R1. Chosen specific effective examples of (1) from the combinatorial library must then be assayed for effectiveness as a protease inhibitor with individually serially varied moieties R2.

The solid phase techniques currently available are not sufficiently developed to enable flexible combinatorial variation of both R1 and R2 in the majority of classes of (1), even in a simple serial manner as single entities, let alone as combinatorial libraries. Thus a solid phase combinatorial library method, enabling the rapid preparation of hundreds or thousands of compounds across many classes of (1) would potentially be extremely attractive for physicochemical / structure-activity profiles in the development of drug candidates. Additionally, such a methodology would expedite the transformation of R1 substrate data derived from the library described in GB 9608457.9 into an effective inhibitor, a process which is currently time consuming using solution based techniques.

It will readily be appreciated by those skilled in the art that a general solid phase combinatorial route to molecules of structure (1) would not be restricted to the

- 4 -

development of protease inhibitors. Any type of interaction e.g. receptor agonists, antagonists for which molecules of type (1) exhibit activity may be developed in a combinatorial manner. Here, a novel solid-phase methodology is described allowing the flexible variation of R1 and R2 in many classes of general structure (1), and allowing a combinatorial approach leading to parallel preparation of many molecules.


10 Background Chemistry - The Current Problem

15 Solid phase based synthesis utilise cross-linked polymers (a resin support) which is functionalised with a chemically reactive unit (a linker). A functional group (carboxylic acid, amine, hydroxyl, sulphydryl etc) from an initial intermediate of the final desired compound is reversibly and covalently attached to the resin through the linker. Sequential chemical transformations of this now resin-bound intermediate to the final compound are then performed. At each stage, excess and spent reagents are removed from the growing resin-bound product by simple filtration and washing - this being the overriding factor providing expedient synthesis compared to solution based synthesis. As a final step, the fully assembled product is released from the solid support by cleavage of the covalent bond between the linker and product functional group.

25 To date, peptides provide the vast majority of compounds of general formula (1) prepared. Traditional solid phase peptide synthesis utilises a linker derivatised resin support to which the C α carboxyl of the C-terminal residue is covalently attached. The desired

- 5 -

sequence is sequentially assembled (using individual elements at each stage to give a single final product or using mixtures of elements at each stage to give a mixture or 'library' of final products). Then the product is released into solution by cleavage of the C-terminal residue - linker bond. This provides the free C-terminal carboxylic acid. To provide alternative C-terminal functionalities different linkers have been developed. However virtually all linkers described to date release a functional group (carboxylic acid, amine, hydroxyl, sulphhydryl etc) present in the final product. Thus an obvious problem arises if the desired compound is devoid of one of the above functionalities, as many classes of (1) are. For example peptidyl acyloxymethyl ketones, of the general formula (2), a potent class of inhibitor of the cysteinyl protease *Der p I*, a major allergen of the house dust mite, are a member of the general class (1), but contain no obvious functional group to which a linker can attach an intermediate to a resin. Therefore current solid phase techniques cannot prepare potential drug candidates of the general structure (2) as single discrete compounds let alone defined libraries of analogues.



Co-pending PCT Application No. PCT/GB96/01707 describes in more detail the cysteinyl protease *Der p I*

SUBSTITUTE SHEET (RULE 26)


- 6 -

inhibitors (2) and their preparation. (Where legally permissible PCT/GB96/01707 is incorporated herein by reference).

A Novel Solid-Phase Based Solution

5 i) Strategy

The only functional element that is always present in (1) is the secondary amide group (3). Thus, the attachment of initial intermediates of general formula (1) through the conserved secondary amide group to a resin support
 10 provides a unique route to any class of (1). Following subsequent solid phase assembly of the desired compound/s, the covalent bond between the linker and now tertiary amide is cleaved to regenerate the conserved secondary amide (3). See Scheme 1 below. During the sequential
 15 chemical transformations leading to the final secondary



- 7 -

amide product, one has two options. Coupling reactions (the addition of a new chemical moiety providing a part of the final product) may be performed using single building blocks, leading to a single final product. Alternatively, each coupling stage may be performed using chemical mixtures, providing a combinatorial library of final products in which both R1 and R2 have been varied. This latter route greatly expands the number and range of drug-like molecules that may be accessed in an overall drug discovery programme.


ii) Chemistry

The vast majority of solid phase synthesis described over the last decade uses side-chain functional group protection which is removed by acidolytic cleavage together with N α -protection removed by base. The wide range of commercially available building blocks are thus based upon this Scheme. A popular strategy in solid phase synthesis is, as a final synthetic step, the concomitant removal of side-chain protection along with product-linker cleavage. Thus, many linkers described in the literature are cleaved from the product by acidolytic treatment. A further desirable feature of a linker is the ability to readily derivatise (i.e. addition of R1-CO- in Scheme 1) with a wide range of reagents. An ideal linker for Scheme 1 should therefore encompass all of the above properties. However, to date, no such linker has been described to our knowledge.

There are a number of backbone amide protecting groups which generate amides upon acidolytic treatment described in the literature. Johnson, Quibell and

- 8 -

Sheppard have described the development of a backbone amide protection system outlined in Scheme 2.




R3 = H or CH3

SCHEME 2

This system (not a linker in its own right) was designed to protect the backbone amide of a peptide (previously attached to the resin through a C-terminal residue-linker moiety) during synthesis. Following completion of peptide assembly, the group was removed as a final step along with side-chain deprotection and peptide-linker cleavage by trifluoroacetic acid (TFA). It was found that in Scheme 2 the use of a 2-hydroxyl (R3 = H) rather than a 2-methoxy (R3 = OCH3) group allowed the subsequent acylation to be performed with a wide range of reagents, through an acyl transfer mechanism. In contrast, the 2-methoxy derivatised system cannot undergo the acyl transfer reaction and was found to have a very limited applicability.

The group of Barany have recently described a backbone amide linker shown in Scheme 3.

- 9 -




SCHEME 3

This linker does not contain the acyl transfer option during acylation and is therefore not of general applicability.

The present invention provides a combination of the elements described in Schemes 2 and 3 and leads to the backbone amide linker system shown in Scheme 4. This now contains an acyl transfer element (i.e. -OY=2-hydroxyl moiety) along with the correct chemical properties of the backbone amide linker making the system compatible with a wide body of commercially available reagents. The linker outlined in Scheme 4 provides us the necessary chemistry to achieve the general goal described in Scheme 1, this being the flexible combinatorial preparation of many libraries of different classes of drug-like molecules with general formula (1), having both R1 and R2 variable simultaneously.


- 10 -



SCHEME 4

and wherein:

X is



Y is H or a side chain functional group protective moiety such as Fmoc;

5 R²¹ is an intermediate form of R₂ which is subsequently chemically transformed to give the desired R₂; and

n is between 2 and 12, preferably 4.

- 11 -

The present invention provides in a first aspect an intermediate compound of general formula (A)




5 for use in a method of preparation of a compound of
general formula (1)





- 12 -

wherein the linker moiety has the general formula (B)



and wherein:

X is



Y is H or a side chain functional group protective moiety
 5 such as Fmoc;


R2¹ is an intermediate form of R2 which is subsequently
 chemically transformed to give the desired R2; and

n is between 2 and 12, preferably 4.


SUBSTITUTE SHEET (RULE 26)

- 13 -

In a second aspect the present invention provides an intermediate compound of general formula (C)





5 wherein the linker moiety has the general formula (B)



- 14 -

and wherein:



X is



Y is H or a side chain functional group protective moiety such as Fmoc;


5 n is between 2 and 12, preferably 4.

The present invention also provides an acyl derivative of an intermediate compound shown above having the general formula (D) (D¹)



- 15 -

The present invention also provides a compound of general formula (E)



for use in a method of preparation of an intermediate compound shown above.


The present invention also provides compounds of general formula (F) and (G)




- 16 -

for use in a method of preparation of a compound (E).

According to the present invention there is provided a method for the preparation of a compound of general formula (1) using an intermediate compound shown above which method includes the following steps:



The invention further provides a method for the preparation of a compound of general formula (E) which method includes the following steps:



- 17 -

The invention also provides compounds which are the products of the methods above.


Also the invention provides for the use of compounds of the invention in a method for the preparation of a combinatorial library of compounds of general formula (1) in which both R1 and R2 are variable.

Preferably in compounds of formula (B) (E) and (G); Y=H and X=(CH₂)_n where n=4.

Example Use of the Novel Technology.


10 Preparation of a Linker

One example of a preparative method for a linker moiety according to the invention is illustrated below:



- 18 -

A second example of a preparative method for a linker moiety according to the invention is illustrated below:



- 19 -

(I) 2,4-Dihydroxybenzaldehyde (mw.138.1, 50g, 0.36 mol) and spray-dried potassium fluoride (mw.58.1, 41.8g, 0.72 mol) were stirred vigorously at 60° C for 20 mins in anhydrous acetonitrile (750 mL); methyl-5-bromovalerate (mw.195.1, 140.4g, 0.72mol) was added in one portion and the mixture brought to gentle reflux for 5 hours. The reaction was allowed to cool to room temperature and the solvent removed *in vacuo*; the residue was partitioned between water (500mL) and ethyl acetate (250mL), the aqueous washed twice more with ethyl acetate (2x150mL) and the combined organic back-washed with water, dried over anhydrous magnesium sulphate, filtered and evaporated to dryness. The resulting red oil was dissolved in methyl tert-butyl ether (150mL), heptane (100mL) added and the product allowed to crystallize out as an off-white solid (mw.252.3, 37.3g, 0.148mol, 41% yield); ¹H NMR (CDCl₃) δ 11.44 (1H, s), 9.69 (1H, s), 7.41 (1H, d, J=8.6 Hz), 6.51 (1H, dd, J=8.6, 2.2 Hz), 6.39 (1H, d, J=2.2 Hz), 4.02 (2H, t, J=5.8 Hz), 3.66 (3H, s), 2.44 (2H, t, J=7.0 Hz), 1.83 (4H, m); IR (film) 1735 cm⁻¹; mp. 62-65°C; ESMS *m/z* 253 (M⁺+1); HPLC rt. 15.4 min, 10-90% B in A, A = 0.1% aq. TFA, B = 10% A in MeCN, linear gradient 25 min, 1.5 mL/min, column = Vydac protein C4, 4.6x250 mm, 5μ particle size.

(II) The product of step (I),


5-(4-Formyl-3-hydroxyphenoxy)pentanoic acid methyl ester (mw. 252.3, 37g, 0.147mol) was dissolved in THF (1200mL) and stirred vigorously at room temperature. To this solution was added lithium hydroxide (mw.41.96, 18.5g, 0.441mol) dissolved in water (600mL) and the mixture stirred for 4 hours. The solvent was reduced *in vacuo* and the resulting oily residue diluted with water (200mL), washed twice with methyl tert-butyl ether (2x500mL), acidified carefully to pH 2 with conc. HCl (vigorous stirring) and extracted with ethyl acetate (4x300mL). The combined ethyl acetate was dried over anhydrous magnesium sulphate, filtered and evaporated to dryness to give the product as a white solid (mw.238.2, 32.1g, 0.135mol, 92% yield); ¹H NMR (CDCl₃) δ 11.26 (2H, br.s), 9.69 (1H, s), 7.41 (1H, d, J=8.6 Hz), 6.51 (1H, dd, J=8.6, 2.2 Hz), 6.40 (1H, d, J=2.2 Hz), 4.02 (2H, t, J=5.9 Hz), 2.44 (2H, t, J=7.0 Hz), 1.84 (4H, m); IR (film) 1697, 1626 cm⁻¹; mp. 88.6-89.1°C; ESMS *m/z* 239 (M⁺+1); HPLC rt. 14.3 min, 10-90% B in A, A = 0.1% aq. TFA, B = 10% A in MeCN, linear gradient 25 min, 1.5 mL/min, column = Vydac protein C4, 4.6x250 mm, 5μ particle size.

- 20 -

Combinatorial Library of Peptidyl Acyloxymethyl Ketones.

Scheme 5 illustrates a potential use of the new solid phase combinatorial technology for the preparation of a library of peptidyl acyloxymethyl ketones as potential
5 inhibitors of the cysteinyl protease *Der p I*.

- 21 -



Where R = aryl, alkyl
 R1', R2' = natural or
 non-natural
 amino-acid
 side-chain
 Z, Y = H, alkyl, halogen etc

SCHEME 5

SUBSTITUTE SHEET (RULE 26)

- 22 -

Currently, there are approximately 200 commercially available Fmoc-NH-CHR1'-COOH building blocks available that could potentially be used in the above Scheme. A large proportion of these could be derivatised to produce the initial resin-bound intermediate in Scheme 5. Thus there are potentially $200^3 = 40\,000$ R1'/R2' variations, together with a virtually unlimited combination of R / Y / Z. Even with the 2-hydroxyl acyl transfer mechanism, certain combinations may be too hindered to be practical. However, greater than 80%, i.e. >32000 will be readily accessible using the new system defined in Scheme 4. The limited applicability of the only currently described backbone amide linker system (Scheme 3) is clearly illustrated here. In comparison to Scheme 4 (according to the invention), Scheme 3 (prior art) would have a practical performance capability in only approximately 10%, i.e. 4000 of all allowable R1' / R2' combinations.


Examples

Libraries of compounds have been synthesised using the novel solid phase combinatorial chemistry of the present invention. Examples are:


Example 1

Libraries of compounds of general formula (H)

- 23 -



wherein R² is selected from the group:



or another primary amine moiety

SUBSTITUTE SHEET (RULE 26)


- 24 -

and wherein R¹ is combinatorially variable.

These libraries may be useful for discovery of protease inhibitors; for example they may be useful for discovery of Aspartyl protease inhibitor.

5 Example 2


Libraries of Statine containing compounds of general formula (J)



10 wherein one or both of R¹ and R⁴ are combinatorially variable.

Example 3

Libraries of diketopiperazine compounds of general formula (K), wherein (K) is an intermediate formed by removal of an N-terminal protecting group from a precursor moiety, and wherein K is unstable and hence automatically cyclises:




- 25 -

wherein R^1 and/or R^2 are combinatorially variable, and R^3 is an alkyl or allyl leaving group. These compounds (J) are cleavable to form cyclic compounds of general formula (L).

5 Example 4

Libraries of compounds of general formula (M)




which can be cyclised and cleaved to provide cyclic compounds of general formula (N) in which AA^1-AA^4 are independently combinatorially variable. It is a particular advantage of the class of compounds (M) that the $C\alpha$ of proline cannot easily be epimerised in the reaction and hence chiral integrity of the cyclic product can be preserved.

Thus according to a further aspect of the invention there are provided libraries of compounds and individual compounds per se of formula (H) (J) (K) and (M) - whether attached to the Backbone Linker or in cleaved form, together with libraries and individual compounds per se of formula (L) and (N).

- 26 -

Claims


1. An intermediate compound of general formula (A)



- 5 for use in a method of preparation of a compound of general formula (1)





wherein the linker moiety has the general formula (B)



- 27 -

and wherein:

X is




Y is H or a side chain functional group protective moiety such as Fmoc;


5 R2¹ is an intermediate form of R2 which is subsequently chemically transformed to give the desired R2; and

n is between 2 and 12, preferably 4.

2. An intermediate compound of general formula (C)





wherein the linker moiety has the general formula (B)



- 28 -

and wherein:



X is



Y is H or a side chain functional group protective moiety such as Fmoc;

5 n is between 2 and 12, preferably 4.


3. An acyl derivative of an intermediate compound according to claim 1 or 2 having the general formula (D) (D¹)



SUBSTITUTE SHEET (RULE 26)


- 29 -

4. A compound of general formula (E)




for use in a method of preparation of an intermediate compound according to claims 1, 2 or 3.

5. A method for the preparation of a compound of general formula (1) using an intermediate compound according to claim 1 or 2 which method includes the following steps:



- 30 -

6. A method for the preparation of a compound of general formula (E) which method includes the following steps:



7. A compound of general formula (F) or (G)




for use in a method according to claim 6 for preparation of a compound (E) according to claim 4.

10 8. The product of the method of claim 5 or 6.


- 31 -

9. Use of compounds according to any of claims 1, 2, 3, 4 or 7 in a method for the preparation of a combinatorial library of compounds of general formula (1) in which both R1 and R2 are variable.


10. A compound or combinatorial library of compounds of formula





wherein



or another primary amine moiety; or




SUBSTITUTE SHEET (RULE 26)




whether attached to a Backbone Linker or in cleaved form.

- 33 -

11. A compound or combinatorial library of compounds of formula



; or




THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 231/10, C07K 1/00, C07C 59/125, 51/367, 47/565, 69/708	A3	(11) International Publication Number: WO 98/17628
		(43) International Publication Date: 30 April 1998 (30.04.98)
(21) International Application Number: PCT/GB97/02914		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 22 October 1997 (22.10.97)		
(30) Priority Data: 9621985.2 22 October 1996 (22.10.96) GB		
(71) Applicant (for all designated States except US): PEPTIDE THERAPEUTICS LIMITED [GB/GB]; 321 Cambridge Science Park, Milton Road, Cambridge CB4 4WG (GB).		
(72) Inventors; and (75) Inventors/Applicants (for US only): JOHNSON, Tony [GB/GB]; 10 Brookside Grove, Littleport, Ely, Cambs. CB6 1JN (GB). QUIBELL, Martin [GB/GB]; 23 Fennec Close, Cherry Hinton, Cambridge CB1 4GG (GB).		
(74) Agent: DAVIES, Jonathan, Mark; Reddie & Grose, 16 Theobalds Road, London WC1X 8PL (GB).		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
		(88) Date of publication of the international search report: 3 September 1998 (03.09.98)

(54) Title: A SOLID-PHASE TECHNOLOGY FOR THE PREPARATION OF AMIDES



(57) Abstract

A method for the solid phase synthesis of compounds of formula (1), in which either or both of R^1 or R^2 are combinatorially variable by a process represented by scheme (4) and wherein: X is (a), (b), (c) or (d); Y is H or a side chain functional group protective moiety such as Fmoc; R^2 is an intermediate form of R^2 which is subsequently chemically transformed to give the desired R^2 ; and n is between 2 and 12, preferably 4. The invention also provides compounds and combinatorial libraries of compounds of formula (1), as well as intermediate compounds for use in the method.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 97/02914

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07C231/10 C07K1/00 C07C59/125 C07C51/367 C07C47/565
C07C69/708

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	MANDAL, S.S. ET AL.: "Role of the central metal ion and ligand charge in the DNA binding and modification by metallosalen complexes" BIOCONJUGATE CHEMISTRY, vol. 8, no. 6, November 1997 - December 1997, pages 798-812, XP002055028 see page 800, column 2, line 46 - page 801, column 1, line 13 ---	4,7
Y	SONSTER, M.F ET AL.: "Acid-labile handles for Fmoc solid-phase synthesis of peptide N-alkylamides" LETTERS IN PEPTIDE SCIENCE, vol. 2, 1995, pages 265-270, XP002055029 see the whole document ---	1-10
	-/--	

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

9 February 1998

Date of mailing of the international search report

20.07.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Janus, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 97/02914

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category ²	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>OFFER, J. ET AL.: "On-resin solid-phase synthesis of asparagine N-linked glycopeptides : ..."</p> <p>JOURNAL OF THE CHEMICAL SOCIETY - PERKIN TRANSACTIONS I,</p> <p>no. 2, 1996,</p> <p>pages 175-182, XP002055030</p> <p>see the whole document</p> <p>---</p>	1-10
Y	<p>JOHNSON, T. ET AL.: "Backbone protection and its application to the synthesis of a difficult phosphopeptide sequence"</p> <p>JOURNAL OF THE CHEMICAL SOCIETY - PERKIN TRANSACTIONS I,</p> <p>no. 7, 1996,</p> <p>pages 719-728, XP002055031</p> <p>see the whole document</p> <p>-----</p>	1-10

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 97/ 02914

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see separate sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

claims : 8 (part), 10 (part)-11

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/

1. Claims: 1-7, 8(part), 9, 10(part)

Solid phase process for the bi-directional preparation of peptides, and intermediates therefor.

2. Claims: 8(part), 10(part)-11

Compounds and combinational libraries of compounds which can be prepared by the general methodology of invention 1.